A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, or therapy-related AML whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aptose Biosciences Inc.

Criteria

Key Inclusion Criteria:

• Age ≥18 years

• Life expectancy of at least 3 months

• ECOG Performance Status ≤ 2

• Patients must be able to swallow capsules

• Adequate hematologic parameters, unless cytopenias are disease caused

• Adequate renal, liver and cardiac functions

Key Exclusion Criteria:

• Patients with GVHD requiring systemic immunosuppressive therapy

• Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinically significant disease related metabolic disorder

• Clinically significant leukostasis

• Treatment with other investigational drugs within 14 days prior to first study treatment administration